This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

FINEARTS-HF - finerenone in heart failure with mildly reduced or preserved ejection fraction

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Finerenone is a selective mineralocorticoid receptor (MR) blocker:

  • inhibits the effects of mineralocorticoids like aldosterone and cortisol when the MR is overactivated

FINEARTS-HF study

  • double-blind trial
  • randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy
  • primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes

Study results:

  • over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P=0.007)
  • total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P=0.006)
  • percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia

Study authors concluded that:

  • patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo

An analysis of FINEARTS-HF found those with recent worsening heart failure event had a higher risk of recurrent heart failure events/CV death, & the absolute benefit of finerenone may be higher in these patients (2).

Reference:

  1. Solomon SD et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. NEJM September 1, 2024.
  2. Desai AS et al. Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial. JACC 29 September 2024.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.